GSK tells in-Pharmatechnologist.com that decision to close Indian API plant was prompted by rising cost of manufacture and availability of third party contractors.
Outsourcing-Pharma.com presents a round-up of the latest contract manufacturing investments, including new screening services for Imaxio, Encap’s renewed push for its CMO biz, and Pernix’s bid to take over Great Southern Laboratories.
South Africa aims to boost its pharmaceutical production sector by developing a 70-strong list of oral solid dose drugs that it will only buy from local manufacturers.
More bad news for troubled CMO Ben Venue Laboratories after European regulators recommend that production of two more drugs – Caelyx and Ceplene – is relocated to other facilities.
in-PharmaTechnologist presents a round-up of issues within the pharmaceutical manufacturing industry, including Novartis’ plans to restart Nebraska ops and problems for Roche at it’s South Carolina facility.
Robert Bosch Packaging Technology has sold a filling line to US firm Pharmalucence Partners, which is expanding its contract pharmaceutical manufacturing business.
UK-based contract manufacturing organisation (CMO) SCM Pharma has struck a deal with urology experts Speciality European Pharma (SEP) to help bring SEP's oncology product, Plenaxis, to the European market.
Albany Molecular Research (AMRI) posted a modest net loss on costs and restructuring charges, but saw revenue grow considerably in the first quarter thanks to contracting business and royalties.
Continuous manufacturing offers significant advantages for drug production in terms of quality and efficiency, but more research and regulatory input is needed to help the pharmaceutical sector reap the benefits according to ISP.
Oxford Biomedica has bought RecipharmCobra Biologics’ manufacturing facility in Oxford, UK, to reduce its reliance on third-party production of its gene delivery technology.
bioMérieux will discontinue manufacturing media products for clinical applications and transfer production of other products made at its Portland, US, site elsewhere as part of a restructuring program.
SCM Pharma says demand for specialised contract manufacturing services is growing as the pharma industry focuses on niche indications, biologics and the development of potent medicines.
SOCMA CEO predicts reintroduction of rejected permanent R&D tax credit plan and urges Congress to act “sooner rather than later” to support US manufacturers.
Cel-Sci’s recently opened “Cold fill” facility has passed its first manufacturing test by completing filling of a batch of the candidate head and neck cancer drug Multikine for a late-stage trial.
Algeta has signed a deal making it the exclusive supplier of Alpharadin (radium-223) to Bayer, prompting the expansion of the production facility at IFE.
Claris has initiated a recall of three antibiotics it manufactures, which are also sold by Sagent, Pfizer and West-Ward, after the FDA warned of contamination.
US biotech Genzyme will pay $175m and cease some manufacturing operations at its facility in Allston, Massachusetts under final terms of Food and Drug Administration (FDA) consent decree.
